[HTML][HTML] Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
SARS-CoV-2 variants of concern (VOC) are more transmissible and may have the potential
for increased disease severity and decreased vaccine effectiveness. We estimated the …
for increased disease severity and decreased vaccine effectiveness. We estimated the …
[HTML][HTML] Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United …
Background There is an urgent public health need to evaluate disease severity in adults
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data …
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data …
Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis
Objectives To compare severity and clinical outcomes from Omicron as compared with the
Delta variant and to compare outcomes between Omicron sublineages. Methods We …
Delta variant and to compare outcomes between Omicron sublineages. Methods We …
[HTML][HTML] COVID-19 booster dose vaccination coverage and factors associated with booster vaccination among adults, United States, March 2022
P Lu, A Srivastav, K Vashist, CL Black… - Emerging infectious …, 2023 - ncbi.nlm.nih.gov
Abstract The Centers for Disease Control and Prevention recommends a COVID-19 vaccine
booster dose for all persons> 18 years of age. We analyzed data from the National …
booster dose for all persons> 18 years of age. We analyzed data from the National …
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a …
SY Tartof, JM Slezak, L Puzniak, V Hong… - The Lancet …, 2022 - thelancet.com
Background The duration of protection against the omicron (B. 1.1. 529) variant for current
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially …
COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially …
Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case
M Saban, V Myers, R Wilf-Miron - Preventive Medicine, 2022 - Elsevier
We present epidemiological data to examine trends in COVID-19 incidence, morbidity and
mortality in Israel as well as changes in vaccine effectiveness, and discuss the impact of the …
mortality in Israel as well as changes in vaccine effectiveness, and discuss the impact of the …
[HTML][HTML] Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with …
A Sheikh, S Kerr, M Woolhouse… - The Lancet Infectious …, 2022 - thelancet.com
Background Since its emergence in November, 2021, in southern Africa, the SARS-CoV-2
omicron variant of concern (VOC) has rapidly spread across the world. We aimed to …
omicron variant of concern (VOC) has rapidly spread across the world. We aimed to …
[HTML][HTML] Evaluation of COVID-19 vaccination strategies with a delayed second dose
Two of the Coronavirus Disease 2019 (COVID-19) vaccines currently approved in the United
States require 2 doses, administered 3 to 4 weeks apart. Constraints in vaccine supply and …
States require 2 doses, administered 3 to 4 weeks apart. Constraints in vaccine supply and …
[HTML][HTML] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA. 1, BA. 2, BA. 2.12. 1, BA. 4, and BA. 5
HF Tseng, BK Ackerson, KJ Bruxvoort, LS Sy… - Nature …, 2023 - nature.com
Studies have reported reduced natural SARS-CoV-2 infection-and vaccine-induced
neutralization against omicron BA. 4/BA. 5 compared with earlier omicron subvariants. This …
neutralization against omicron BA. 4/BA. 5 compared with earlier omicron subvariants. This …
Odds of hospitalization for COVID-19 after 3 vs 2 doses of mRNA COVID-19 vaccine by time since booster dose
Methods| This study included adults who received either 2 or 3 doses of an mRNA COVID-
19 vaccine and were hospitalized between October 1, 2021, and July 26, 2022, within the …
19 vaccine and were hospitalized between October 1, 2021, and July 26, 2022, within the …